NASDAQ · EDSA
Edesa Biotech, Inc.
$2.70+$0.14 (+5.47%)
Edesa Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.71% below the high.
Loading market information…
NASDAQ · DWTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Dogwood Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dogwood Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Feb 26, 2025 |
| -$5.90-333.6% vs estimate |
| $0.00 |
| Q3 2024 | Nov 7, 2024 | -$2.05-73.73% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.70+$0.14 (+5.47%)
Edesa Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.71% below the high.
$0.98-$0.01 (-1.01%)
Cocrystal Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.3% below the high.
$13.85-$3.97 (-22.28%)
Sensei Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.32% below the high.
$6.36-$0.22 (-3.34%)
Bolt Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$1.22-$0.02 (-1.61%)
Cellectar Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.04% below the high.
$0.83+$0.00 (+0.35%)
Imunon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.61% below the high.
$0.30-$0.06 (-16.34%)
Traws Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.68% below the high.
$2.11+$0.13 (+6.57%)
Ernexa Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.6% below the high.
